Skip to main content

[Fam-]trastuzumab deruxtecan shows promising clinical activity with a high and durable response rate in patients with HER2-mutated NSCLC.

Read More ›

Treatment with gefitinib in the adjuvant setting is associated with enhanced quality of life in patients with early-stage NSCLC and EGFR mutations. Read More ›

Ensartinib may be a viable treatment option for some forms of secondary ALK alterations. Read More ›

Similar progression-free survival and 2-year overall survival rates reported for both treatment groups, with more grade ≥3 treatment-related adverse events reported in the afatinib + cetuximab group. Read More ›

Study evaluated the benefits of afatinib in Asian and non-Asian patients who had not received EGFR-TKI therapy for their EGFR-mutant NSCLC. Read More ›

Patients with untreated advanced NSCLC with EGFR mutations achieved improved progression-free survival with treatment with gefitinib and carboplatin plus pemetrexed compared with gefitinib alone. Read More ›

Researchers report higher overall response rate, median duration of response, and median progression-free survival in treatment-naïve patients with a MET exon 14 skipping mutation compared with previously treated patients. Read More ›

Researchers reported improved overall survival in patients with nonsquamous non–small-cell lung cancer with EGFR mutations. Read More ›

Tarloxotinib treatment was well tolerated and sizeable percentages of patients in both study cohorts achieved either partial response or stable disease. Read More ›

Osimertinib shows promise as an adjuvant treatment for patients with stage IB to IIIA EGFR mutation–positive NSCLC. Read More ›

Page 9 of 16